Immunis, Inc., a private biotech transforming the field of cellular secretome therapeutics, is excited to reveal that its esteemed Chairman, Dr. Hans Keirstead, will be a featured speaker at the upcoming 2024 Biotech Showcase in San Francisco. The Biotech Showcase is a distinguished event, renowned for bringing together global leaders in biotechnology, pharmaceuticals, and finance to explore the industry’s latest trends and innovations. This year’s conference focuses on drug development in areas including oncology, cell and gene therapy, and rare diseases.

Dr. Hans Keirstead, a venerated scientist with an impressive track record of founding multiple, successful biotech companies, will present Immunis’ cutting edge immunomodulatory secretome aimed at combating age-related diseases. The company’s leading product, IMMUNA, is currently in Phase 1/2a clinical trials and has shown promising pre-clinical results in enhancing muscle regeneration, muscle function, and metabolism. Dr. Keirstead will highlight IMMUNA’s transformative journey from scientific production to first-in-human clinical trials, underscoring the significant potential of IMMUNA to revolutionize therapeutic solutions.

The Biotech Showcase is more than just a conference; it’s a platform for the convergence of academic research and industrial innovation, setting the stage for the future of medical treatment. With visionaries like Dr. Hans Keirstead sharing their insights and experiences, the event promises to be an enlightening experience for professionals, researchers, and enthusiasts in the industry. We invite all to join Immunis at the 2024 Biotech Showcase, an incredible event that will surely reinvent the future of biomedicine.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com